GLP-1–Based Therapies and the Exocrine Pancreas: More Light, or Just More Heat?

por Gale, Edwin A.M.
Publicado 2012

Response to Comment on: Butler et al. A Critical Analysis of the Clinical Use of Incretin-Based Therapies: Are the GLP-1 Therapies Safe? Diabetes Care 2013;36:2118–2125

por Gale, Edwin A.M.
Publicado 2013

New Hypoglycaemic Therapies

por Gale, Edwin A M
Publicado 2000

Diabetes, Insulin Use, and Cancer Risk: Are Observational Studies Part of the Solution–or Part of the Problem?

por Johnson, Jeffrey A., Gale, Edwin A.M.
Publicado 2010

Reversing type 1 diabetes with stem cell–derived islets: a step closer to the dream?

por Butler, Peter C., Gale, Edwin A.M.
Publicado 2022

The insulin market reaches 100

por Beran, David, Gale, Edwin A. M., Yudkin, John S.
Publicado 2022

A Critical Analysis of the Clinical Use of Incretin-Based Therapies : Are the GLP-1 therapies safe?

por Butler, Peter C., Elashoff, Michael, Elashoff, Robert, Gale, Edwin A.M.
Publicado 2013

Productivity of authors in the field of diabetes: bibliographic analysis of trial publications

por Holleman, Frits, Uijldert, Mick, Donswijk, Lennart F, Gale, Edwin A M
Publicado 2015

Mortality After Incident Cancer in People With and Without Type 2 Diabetes: Impact of metformin on survival

por Currie, Craig J., Poole, Chris D., Jenkins-Jones, Sara, Gale, Edwin A.M., Johnson, Jeffrey A., Morgan, Christopher Ll.
Publicado 2012

Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials: A position statement of the American Diabetes A...

por Skyler, Jay S., Bergenstal, Richard, Bonow, Robert O., Buse, John, Deedwania, Prakash, Gale, Edwin A.M., Howard, Barbara V., Kirkman, M. Sue, Kosiborod, Mikhail, Reaven, Peter, Sherwin, Robert S.
Publicado 2009